Nilotinib is effective in imatinib and sunitinib resistant GIST: a case report.

Abstract

We report on the case of a 65-year-old male patient who had an imatinib- and sunitinib-resistant gastro-intestinal stromal tumor. Partial response was achieved with nilotinib treatment given in a compassionate-use program. Efficacy and tolerability of nilotinib in patients with refractory gastrointestinal stromal tumor are briefly discussed.

• Authors: Omer Dizdar, Suayib Yalcin
• Journal: Hepato-gastroenterology (Hepatogastroenterology) 2011 May-Jun Vol. 58 Issue 107-108 Pg. 859-60 ISSN: 0172-6390 [Print] Greece
• PMID: 21830404 (Publication Type: Case Reports, Journal Article)

Chemical References

• Benzamides
• Indoles
• Piperazines
• Pyrimidines
• Pyrroles
• Imatinib Mesylate
• nilotinib
• Sunitinib

Topics

• Aged
• Benzamides
• Drug Resistance, Neoplasm
• Gastrointestinal Stromal Tumors (drug therapy)
• Humans
• Imatinib Mesylate
• Indoles (therapeutic use)
• Male
• Piperazines (therapeutic use)
• Pyrimidines (adverse effects, therapeutic use)
• Pyrroles (therapeutic use)
• Sunitinib